239 related articles for article (PubMed ID: 29222126)
1. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases.
Dubey D; Lennon VA; Gadoth A; Pittock SJ; Flanagan EP; Schmeling JE; McKeon A; Klein CJ
Neurology; 2018 Jan; 90(2):e103-e110. PubMed ID: 29222126
[TBL] [Abstract][Full Text] [Related]
2. Amphiphysin-IgG autoimmune neuropathy: A recognizable clinicopathologic syndrome.
Dubey D; Jitprapaikulsan J; Bi H; Do Campo RV; McKeon A; Pittock SJ; Engelstad JK; Mills JR; Klein CJ
Neurology; 2019 Nov; 93(20):e1873-e1880. PubMed ID: 31624089
[TBL] [Abstract][Full Text] [Related]
3. Collapsin Response-Mediator Protein 5-Associated Retinitis, Vitritis, and Optic Disc Edema.
Cohen DA; Bhatti MT; Pulido JS; Lennon VA; Dubey D; Flanagan EP; Pittock SJ; Klein CJ; Chen JJ
Ophthalmology; 2020 Feb; 127(2):221-229. PubMed ID: 31676123
[TBL] [Abstract][Full Text] [Related]
4. Predicting disability and mortality in CV2/CRMP5-IgG associated paraneoplastic neurologic disorders.
Uysal SP; Li Y; Thompson NR; Milinovich A; Abbatemarco JR; Cohen JA; Conway DS; Ontaneda D; Morren JA; Kunchok A
Ann Clin Transl Neurol; 2024 Mar; 11(3):710-718. PubMed ID: 38251800
[TBL] [Abstract][Full Text] [Related]
5. Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments.
Shah S; Vazquez Do Campo R; Kumar N; McKeon A; Flanagan EP; Klein C; Pittock SJ; Dubey D
Neurology; 2021 Jan; 96(4):e632-e639. PubMed ID: 33208548
[TBL] [Abstract][Full Text] [Related]
6. Collapsin response mediator protein 5-associated optic neuropathy: clinical characteristics, radiologic clues, and outcomes.
Yan R; Mao Y; Zeng H; Liu Q; Jiang H; Peng J; Yang Q; Cui S; Liu L; Guo Y; Wang J
Front Neurol; 2023; 14():1163615. PubMed ID: 37448746
[TBL] [Abstract][Full Text] [Related]
7. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG.
Cross SA; Salomao DR; Parisi JE; Kryzer TJ; Bradley EA; Mines JA; Lam BL; Lennon VA
Ann Neurol; 2003 Jul; 54(1):38-50. PubMed ID: 12838519
[TBL] [Abstract][Full Text] [Related]
8. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients.
Gadoth A; Pittock SJ; Dubey D; McKeon A; Britton JW; Schmeling JE; Smith A; Kotsenas AL; Watson RE; Lachance DH; Flanagan EP; Lennon VA; Klein CJ
Ann Neurol; 2017 Jul; 82(1):79-92. PubMed ID: 28628235
[TBL] [Abstract][Full Text] [Related]
9. [Neurologic paraneoplastic syndrome with anti-CV2/CRMP5 antibodies revealing a small cell lung cancer. Effectiveness of the lung cancer treatment].
Rosencher L; Maisonobe T; Lavole A; Milleron B; Ferroir JP
Rev Neurol (Paris); 2012 Apr; 168(4):371-4. PubMed ID: 22387203
[TBL] [Abstract][Full Text] [Related]
10. Paraneoplastic Hu and CRMP5 antibodies are present in smokers without cancer or neurological disease.
Qvale TH; Storstein A; Mazengia K; Eagan TM; Bakke PS; Vedeler CA
Respirology; 2014 Jul; 19(5):730-4. PubMed ID: 24697843
[TBL] [Abstract][Full Text] [Related]
11. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.
Honnorat J; Cartalat-Carel S; Ricard D; Camdessanche JP; Carpentier AF; Rogemond V; Chapuis F; Aguera M; Decullier E; Duchemin AM; Graus F; Antoine JC
J Neurol Neurosurg Psychiatry; 2009 Apr; 80(4):412-6. PubMed ID: 18931014
[TBL] [Abstract][Full Text] [Related]
12. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients.
Camdessanché JP; Antoine JC; Honnorat J; Vial C; Petiot P; Convers P; Michel D
Brain; 2002 Jan; 125(Pt 1):166-75. PubMed ID: 11834602
[TBL] [Abstract][Full Text] [Related]
13. Demyelinating neuropathy with anti-CRMP5 antibodies predating diagnosis of breast carcinoma: favorable outcome after cancer therapy.
Samarasekera S; Rajabally YA
Muscle Nerve; 2011 May; 43(5):764-6. PubMed ID: 21484830
[TBL] [Abstract][Full Text] [Related]
14. Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy.
Jarius S; Ringelstein M; Haas J; Serysheva II; Komorowski L; Fechner K; Wandinger KP; Albrecht P; Hefter H; Moser A; Neuen-Jacob E; Hartung HP; Wildemann B; Aktas O
J Neuroinflammation; 2016 Oct; 13(1):278. PubMed ID: 27776522
[TBL] [Abstract][Full Text] [Related]
15. Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
Jones AL; Flanagan EP; Pittock SJ; Mandrekar JN; Eggers SD; Ahlskog JE; McKeon A
JAMA Neurol; 2015 Nov; 72(11):1304-12. PubMed ID: 26414229
[TBL] [Abstract][Full Text] [Related]
16. A case of severe chronic progressive axonal polyradiculoneuropathy temporally associated with anti-CV2/CRMP5 antibodies.
Hannawi Y; Goldsmith CE; Kass JS; Olar A; Ubogu EE; Kalkonde YV
J Clin Neuromuscul Dis; 2013 Sep; 15(1):13-8. PubMed ID: 23965404
[TBL] [Abstract][Full Text] [Related]
17. Inositol 1,4,5-trisphosphate receptor type 1 autoantibody (ITPR1-IgG/anti-Sj)-associated autoimmune cerebellar ataxia, encephalitis and peripheral neuropathy: review of the literature.
Jarius S; Bräuninger S; Chung HY; Geis C; Haas J; Komorowski L; Wildemann B; Roth C
J Neuroinflammation; 2022 Jul; 19(1):196. PubMed ID: 35907972
[TBL] [Abstract][Full Text] [Related]
18. Peripheral neuropathies associated with antibodies directed to intracellular neural antigens.
Antoine JC
Rev Neurol (Paris); 2014 Oct; 170(10):570-6. PubMed ID: 25194475
[TBL] [Abstract][Full Text] [Related]
19. Neurochondrin neurological autoimmunity.
Shelly S; Kryzer TJ; Komorowski L; Miske R; Anderson MD; Flanagan EP; Hinson SR; Lennon VA; Pittock SJ; McKeon A
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31511329
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of serum antibodies to GD1b in immune-mediated neuropathies.
Taams NE; Notermans NC; Fokkink WR; Tio-Gillen AP; Huizinga R; Schreurs MWJ; Jacobs BC
J Peripher Nerv Syst; 2018 Dec; 23(4):227-234. PubMed ID: 30101437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
